EMA Authorised: Myalepta (Metreleptin) — Chiesi Farmaceutici S.p.A.

View source ↗

Summary

EMA authorised Myalepta (metreleptin) for lipodystrophy, including familial partial lipodystrophy, with orphan medicine designation; the marketing authorisation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Partial Lipodystrophy
• Lipodystrophy

Drugs mentioned

• Myalepta (metreleptin)

Snippet

Status: Authorised. Therapeutic area: Lipodystrophy, Familial Partial. MAH: Chiesi Farmaceutici S.p.A.. Decision date: 03/11/2025. Orphan medicine